For patients with mixed metabolic- and alcohol-associated liver disease (or ongoing moderate alcohol use) who otherwise meet presumed F2–F3 criteria by NITs, how do you operationalize initiation and monitoring of a GLP-1 receptor agonist, particularly how you interpret NIT trends when alcohol intake (and inflammation) may be changing during treatment?